RxDoctor Payments Data

Michael Gilbert, MD

Gastroenterology · Concord, NHNPI 1538176326

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 9 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $142 and has fallen 52.5% since, to $68 in 2025. That places this record below the midpoint for gastroenterology clinicians in NH, where the typical reported total is $653.

$367in general payments, 2019–2025

Across 17 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$86
  • AbbVie$68
  • Pfizer$60
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45
  • Takeda Pharmaceuticals U.S.A., Inc.$32
  • Sanofi$25
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$367100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$367 in reported general payments places this provider in the 35th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$9,346
Medicare patients
56
Services billed
84

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin11$25,198
Mesalamine21$4,143
Omeprazole127$2,109
Colestipol Hcl26$1,130
Pantoprazole Sodium35$676
Dicyclomine Hcl28$510
Neomycin Sulfate12$283
Esomeprazole Magnesium14$238
Ondansetron OdtOndansetron12$222
Famotidine12$63
Lactulose38$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$45$25,19811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Concord

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →